Matches in Wikidata for { <http://www.wikidata.org/entity/Q96143305> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q96143305 description "clinical trial" @default.
- Q96143305 description "ensayo clínico" @default.
- Q96143305 description "ensayu clínicu" @default.
- Q96143305 description "klinisch onderzoek" @default.
- Q96143305 description "клінічне випробування" @default.
- Q96143305 description "临床试验" @default.
- Q96143305 name "APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL)" @default.
- Q96143305 name "APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL)" @default.
- Q96143305 type Item @default.
- Q96143305 label "APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL)" @default.
- Q96143305 label "APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL)" @default.
- Q96143305 prefLabel "APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL)" @default.
- Q96143305 prefLabel "APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL)" @default.
- Q96143305 P1050 Q96143305-1A65285A-B911-411D-BFA0-86F226C031BE @default.
- Q96143305 P1050 Q96143305-4C7A9366-8EE0-4723-96C3-9FC60FA4AE92 @default.
- Q96143305 P1132 Q96143305-730DD4B7-161F-4E09-A2AD-5C06753CE0BF @default.
- Q96143305 P1476 Q96143305-D4E76732-AD09-479A-8383-62540159EBD8 @default.
- Q96143305 P1813 Q96143305-BED87C12-D11F-435B-91D8-D858D8512001 @default.
- Q96143305 P2899 Q96143305-D90E27A2-CF53-455A-8567-1C3078CAF80E @default.
- Q96143305 P3098 Q96143305-7B1CD802-97A0-46C8-840E-A6A3FCA2AA9E @default.
- Q96143305 P31 Q96143305-4225BEA8-2496-46EB-B566-DFDD2AE34DCC @default.
- Q96143305 P4844 Q96143305-3B53EB31-1F76-442C-B8C3-6296B235A254 @default.
- Q96143305 P580 Q96143305-0C7E4F63-80BA-4100-BFB8-5D63A14894D9 @default.
- Q96143305 P582 Q96143305-52F07F7A-5E26-470C-A1A1-D02D2C3C3007 @default.
- Q96143305 P6099 Q96143305-3EC9D184-AA4D-492D-94C0-0D96B20C3A40 @default.
- Q96143305 P6099 Q96143305-F9BF3CB5-1E88-4F06-84A7-B825BD530E2E @default.
- Q96143305 P8005 Q96143305-7F0ACEBC-C885-430E-A4D4-3F3E50668C90 @default.
- Q96143305 P8363 Q96143305-1999381A-BEB9-456E-BD5E-4A08E5C7C915 @default.
- Q96143305 P1050 Q208414 @default.
- Q96143305 P1050 Q29496 @default.
- Q96143305 P1132 "+116" @default.
- Q96143305 P1476 "Phase 1 and Dose Expansion Study of APR-246 in Combination With Ibrutinib or Venetoclax-based Therapy in Subjects With TP53-Mutant R/R NHL Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)" @default.
- Q96143305 P1813 "R/R" @default.
- Q96143305 P2899 "+18" @default.
- Q96143305 P3098 "NCT04419389" @default.
- Q96143305 P31 Q30612 @default.
- Q96143305 P4844 Q23671272 @default.
- Q96143305 P580 "2020-09-01T00:00:00Z" @default.
- Q96143305 P582 "2022-12-01T00:00:00Z" @default.
- Q96143305 P6099 Q42824440 @default.
- Q96143305 P6099 Q5452194 @default.
- Q96143305 P8005 Q76649614 @default.
- Q96143305 P8363 Q78089383 @default.